A Phase 1 interventional study of RO7669330 and Syfovre™ in Geographic Atrophy and Age-related Macular Degeneration, sponsored by Hoffmann-La Roche. Terminated at 17 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Geographic Atrophy by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Geographic Atrophy · Hoffmann-La Roche.
Among the 16 studies in Geographic Atrophy by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 1, and was the 15th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →2 of the 16 studies in Geographic Atrophy by Hoffmann-La Roche are open now, in 2 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Genentech, Inc. · Sites in United States, Israel
Ages 50+
By country, each count listing its studies:
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2025.
This study's enrollment of 27 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 144 across the 14 interventional studies, 249 across the 2 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Geographic Atrophy by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ocular Exclusion Criteria for the Study Eye:
Ocular Exclusion Criteria for the Non-Study Eye:
- Non-functioning non-study eye, defined as either: BCVA of hand motion or worse and/or no physical presence of eye
Ocular Exclusion Criteria for Both Eyes:
Participants will receive multiple doses of RO7669330 as IVT injections in the study eye with additional cohorts of participants receiving higher doses of RO7669330.
Drug: RO7669330
Participants will receive either Syfovre, 15 milligrams (mg) or Izervay, 2 mg, as an IVT injection in the study eye.
Drug: Syfovre™ · Drug: Izervay™
Participants will receive RO7669330 (at two dose levels) or the active comparator (either Syfovre or Izervay), as an IVT injection in the study eye.
Drug: RO7669330 · Drug: Syfovre™ · Drug: Izervay™
RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
Syfovre™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
Also known as: Pegcetacoplan injection
Izervay™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
Also known as: Avacincaptad pegol IVT solution
Number of Participants With Adverse Events (AEs)
Time frame: Up to a maximum of 34 weeks
Number of Participants With Abnormalities Recorded in Standard Ophthalmological Assessments
The standard ophthalmological assessments that will be conducted may include the following: slit-lamp, indirect ophthalmology, intraocular pressure (IOP), best corrected visual acuity (BCVA), spectral domain optical coherence tomography (SD-OCT), fundus fluorescein angiography (FFA), and color fundus photography (CFP).
Time frame: Up to a maximum of 34 weeks
Part 1A and Part 2: Ocular and Systemic Concentration of RO7669330
Time frame: Up to a maximum of Week 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Feb 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pegcetacoplan · Avacincaptad pegol